Pfizer Intrinsic Value
PFIZER • Healthcare
Current Stock Price
₹4720.50
Primary Intrinsic Value
₹4105.20
Market Cap
₹217.1K Cr
-60.0%
Downside
Median Value
₹1888.20
Value Range
₹1416 - ₹4105
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
PFIZER Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4105.20 | ₹3284.16 - ₹4926.24 | -13.0% | EPS: ₹186.60, Sector P/E: 22x |
| Book Value Method | asset | ₹1833.48 | ₹1650.13 - ₹2016.83 | -61.2% | Book Value/Share: ₹916.74, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1416.15 | ₹1274.54 - ₹1557.77 | -70.0% | Revenue/Share: ₹618.91, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2613.04 | ₹2351.74 - ₹2874.34 | -44.6% | EBITDA: ₹1202.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1888.20 | ₹1510.56 - ₹2265.84 | -60.0% | CF Growth: 11.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹1416.15 | ₹1274.54 - ₹1557.77 | -70.0% | EPS Growth: 8.7%, Fair P/E: 6.9x |
| Growth Adjusted P/E | growth | ₹2821.11 | ₹2539.00 - ₹3103.22 | -40.2% | Revenue Growth: 1.6%, Adj P/E: 15.1x |
| ROE Based Valuation | profitability | ₹2970.43 | ₹2673.39 - ₹3267.47 | -37.1% | ROE: 20.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1833.48 | ₹1650.13 - ₹2016.83 | -61.2% | EPS: ₹186.60, BVPS: ₹916.74 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
PFIZER Intrinsic Value Analysis
What is the intrinsic value of PFIZER?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Pfizer (PFIZER) is ₹1888.20 (median value). With the current market price of ₹4720.50, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹1416.15 to ₹4105.20, indicating ₹1416.15 - ₹4105.20.
Is PFIZER undervalued or overvalued?
Based on our multi-method analysis, Pfizer (PFIZER) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 28.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 20.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.58x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Pfizer
Additional stock information and data for PFIZER
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹660 Cr | ₹625 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹257 Cr | ₹257 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹356 Cr | ₹338 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹667 Cr | ₹380 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹427 Cr | ₹193 Cr | Positive Free Cash Flow | 7/10 |